Open AccessSimilar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
Author(s) -
K. Robertson,
P. Maruff,
L.L. Ross,
D. Wohl,
C.B. Small,
H. Edelstein,
M.S. Shaefer
Publication year - 2019
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/fts5-j569
Subject(s) - abacavir , atazanavir , emtricitabine , lamivudine , ritonavir , tenofovir , neurocognitive , virology , medicine , human immunodeficiency virus (hiv) , pharmacology , antiretroviral therapy , viral load , psychiatry , virus , hepatitis b virus , cognition